CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity patte similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.
Host
Mouse
Immunogen
Recombinant human CD19 protein
Positive Control
Tonsil, Lymph Node or Spleen
Reactivity
Human
Recombinant
FALSE
Regulatory
RUO
Swissprot
P15391
Uniprot
652262
Gene Id
930
Buffer
200μg/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA; 0.05% azide. Also available WITHOUT BSA; azide at 1.0mg/ml.
Concentration
1.0mg/ml
Description
There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.
Purity
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
Applications
FACS, IF
Description
Optimal dilution for a specific application should be determined., FACS ; IF